Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed

Cardiovascular Research

Volumn 57, Issue 2, 2003, Pages 535-543

  Tatchum Talom, Rabelais ^a   Martel, Céline ^a   Labrie, Fernand ^a   Marette, André ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Arteries; Hormones; Receptors; Vasoconstriction dilation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACOLBIFENE; ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; ENDOTHELIN 1; ESTRADIOL; FULVESTRANT; INDOMETACIN; METHOXAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PIPENDOXIFENE; POTASSIUM CHANNEL BLOCKING AGENT; PROSTANOID; RALOXIFENE; REACTIVE OXYGEN METABOLITE; SCAVENGER; SCH 57068; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; FEMALE; GONADECTOMY; ISOLATED ORGAN; LIPOGENESIS; MALE; MESENTERY BLOOD FLOW; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; MALE; METHOXAMINE; NITRIC OXIDE; PIPERIDINES; POTASSIUM CHANNELS; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPLANCHNIC CIRCULATION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 12244304833     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00666-1     Document Type: Article

References (34)

1. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 95:1997;252-264.
2. Falkenstein E., Tillmann H.C., Christ M., Feuring M., Wehling M. Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev. 52:2000;513-556.
3. Rubanyi G.M., Freay A.D., Kauser K., et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest. 99:1997;2429-2437.
4. Haynes M.P., Russell K.S., Bender J.R. Molecular mechanisms of estrogen actions on the vasculature. J Nucl Cardiol. 7:2000;500-508.
5. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1999;1801-1811.
6. Stampfer M.J., Colditz G.A., Willett W.C., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 325:1991;756-762.
7. Labrie F., Labrie C., Belanger A., et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 69:1999;51-84.
8. Labrie F., Labrie C., Belanger A., et al. Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. Adv Protein Chem. 56:2001;293-368.
9. McDonnell D.P. The Molecular Pharmacology of SERMs. Trends Endocrinol Metab. 10:1999;301-311.
10. Barrett-Connor E., Cox D.A., Anderson P.W. The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrinol Metab. 10:1999;320-325.
11. Figtree G.A., Lu Y., Webb C.M., Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 100:1999;1095-1101.
12. Figtree G.A., Webb C.M., Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther. 295:2000;519-523.
13. Christensen K.L., Mulvany M.J. Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats. J Vasc Res. 30:1993;73-79.
14. Martel C., Provencher L., Li X., et al. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J Steroid Biochem Mol Biol. 64:1998;199-205.
15. Tatchum-Talom R., Atkinson J. Disruption of the rat mesenteric arterial bed endothelial function by air perfusion. Life Sci. 60:1997;2407-2416.
16. Tatchum-Talom R., Martel C., Marette A. Influence of estrogen on aortic stiffness and endothelial function in female rats. Am J Physiol Heart Circ Physiol. 282:2002;H491-H498.
17. Misurski D., Tatchum-Talom R., McNeill J.R., Gopalakrishnan V. Vanadate-evoked relaxation of the perfused rat mesenteric vascular bed. Life Sci. 67:(11):2000;1369-1379.
18. Adeagbo A.S. Endothelium-derived hyperpolarizing factor: characterization as a cytochrome P450 1A-linked metabolite of arachidonic acid in perfused rat mesenteric prearteriolar bed. Am J Hypertens. 10:(7):1997;763-771.
19. Jiang C.W., Sarrel P.M., Lindsay D.C., Poole-Wilson P.A., Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro. Br J Pharmacol. 104:1991;1033-1037.
20. Shaw L., Taggart M.J., Austin C. Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. Br J Pharmacol. 129:2000;555-565.
21. Freay A.D., Curtis S.W., Korach K.S., Rubanyi G.M. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Circ Res. 81:1997;242-248.
22. Gonzales R.J., Kanagy N.L. Endothelium-independent relaxation of vascular smooth muscle by 17 beta-estradiol. J Cardiovasc Pharmacol Ther. 4:1999;227-234.
23. Hugel S., Neubauer S., Lie S.Z., et al. Multiple mechanisms are involved in the acute vasodilatory effect of 17beta-estradiol in the isolated perfused rat heart. J Cardiovasc Pharmacol. 33:1999;852-858.
24. Jiang C., Poole-Wilson P.A., Sarrel P.M., Mochizuki S., Collins P., MacLeod K.T. Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 106:1992;739-745.
25. Teoh H., Quan A., Leung S.W., Man R.Y. Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arterie. Br J Pharmacol. 129:2000;1301-1308.
26. Hodges Y.K., Tung L., Yan X.D., Graham J.D., Horwitz K.B., Horwitz L.D. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 101:2000;1792-1798.
27. Gauthier S., Caron B., Cloutier J., et al. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem. 40:1997;2117-2122.
28. Rahimian R., Laher I., Dube G., van Breemen C. Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J Pharmacol Exp Ther. 283:1997;116-122.
29. Ma X.L., Gao F., Yao C.L., et al. Nitric oxide stimulatory and endothelial protective effects of idoxifene, a selective estrogen receptor modulator, in the splanchnic artery of the ovariectomized rat. J Pharmacol Exp Ther. 295:2000;786-792.
30. Buus N.H., Simonsen U., Pilegaard H.K., Mulvany M.J. Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol. 129:2000;184-192.
31. Barbacanne M.A., Rami J., Michel J.B., et al. Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: possible role of decreased endothelium-derived superoxide anion production. Cardiovasc Res. 41:1999;672-681.
32. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;605-613.
33. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). J. Am. Med. Assoc. 288:2002;49-57.
34. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. J. Am. Med. Assoc. 288:2002;321-333.